Immune Monitoring to Facilitate Belatacept Monotherapy
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
- To determine the utility of novel blood-based immune monitoring tools (Allosure and
Trugraf) to facilitate belatacept monotherapy.
- To determine the percent of belatacept-treated renal transplant patients that can be
safely converted to belatacept monotherapy.